Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.ajog.2012.12.023
Title: Safety of macrolides during pregnancy
Authors: Lin, K.J.
Mitchell, A.A.
Yau, W.-P. 
Louik, C.
Hernández-Díaz, S.
Keywords: azithromycin
clarithromycin
congenital malformations
erythromycin
macrolides
Issue Date: Mar-2013
Source: Lin, K.J., Mitchell, A.A., Yau, W.-P., Louik, C., Hernández-Díaz, S. (2013-03). Safety of macrolides during pregnancy. American Journal of Obstetrics and Gynecology 208 (3) : 221e1-221e8. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ajog.2012.12.023
Abstract: Objective: Prior studies have reported increased risks of congenital heart defects (CHD) and pyloric stenosis (PS) after prenatal exposure to macrolide antibiotics. We sought to assess the association between maternal use of erythromycin and nonerythromycin macrolides and the risks of CHD and PS. Study Design: Among participants in the Slone Epidemiology Center Birth Defects Study from 1994 through 2008, we identified 4132 infants with CHD and 735 with PS as cases, and 6952 infants without any malformation as controls. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with use of erythromycin or nonerythromycin macrolides in each trimester using conditional logistic regression and adjusting for risk factors for CHD and PS, fever, specific types of infections, and their associated treatments. Results: During the first trimester, 0.4% and 0.7% of control women had used erythromycin and nonerythromycin macrolides, respectively. Compared to non-use during pregnancy, first-trimester exposure to erythromycin was not associated with an increased risk of CHD (OR, 1.3; 95% CI, 0.6-2.6) or PS (OR, 0.9; 95% CI, 0.3-3.0). The corresponding ORs for nonerythromycin macrolides were 0.7 (95% CI, 0.4-1.3) for CHD and 1.7 (95% CI, 0.6-4.6) for PS. We found no association between third-trimester exposure to erythromycin or nonerythromycin macrolides and the risk of PS. Hypothesis generation analyses did not identify appreciable associations between maternal use of macrolides and other common specific birth defects. Conclusion: We found no meaningful associations between the risks of CHD, PS, and other common malformations in relation to use of macrolides in pregnancy. © 2013 Mosby, Inc.
Source Title: American Journal of Obstetrics and Gynecology
URI: http://scholarbank.nus.edu.sg/handle/10635/106320
ISSN: 00029378
DOI: 10.1016/j.ajog.2012.12.023
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

38
checked on Feb 15, 2018

WEB OF SCIENCETM
Citations

22
checked on Feb 5, 2018

Page view(s)

36
checked on Feb 20, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.